Whipplewood Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$26.4K Sell
22
-69
-76% -$70.5K 0.02% 174
2026
Q1
$83.7K Buy
91
+62
+214% +$62.9K 0.04% 213
2025
Q4
$31.2K Buy
29
+17
+142% +$16.3K 0.02% 229
2025
Q3
$9.16K Sell
12
-313
-96% -$233K 0.01% 265
2025
Q2
$253K Sell
325
-18
-5% -$14K 0.14% 144
2025
Q1
$291K Sell
343
-9
-3% -$7.49K 0.17% 123
2024
Q4
$272K Buy
+352
New +$291K 0.15% 127

Other funds holding LLY

Whipplewood Advisors's LLY Position: Q2 2026 in Review

Whipplewood Advisors reduced its Eli Lilly (LLY) stake by 76% in Q2 2026, selling an estimated $70.5K and leaving 22 shares worth $26.4K. The position accounts for 0.02% of the portfolio, ranked #174.

Whipplewood Advisors first reported a position in LLY in Q4 2024 and has held it in 7 quarters since. The position peaked at $291K in Q1 2025. 4,642 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Whipplewood Advisors held 22 shares of Eli Lilly worth $26.4K as of Q2 2026.
  • Whipplewood Advisors sold 69 Eli Lilly shares in Q2 2026, an estimated $70.5K.
  • Eli Lilly made up 0.02% of Whipplewood Advisors's portfolio in Q2 2026, its #174 holding.
  • Whipplewood Advisors first reported a position in Eli Lilly in Q4 2024 and has held it in 7 quarters since.
  • Whipplewood Advisors's Eli Lilly position peaked at $291K in Q1 2025.
  • 4,642 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Whipplewood Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.